MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
MBM-02 (Tempol) is an HIF-1 and HIF-2 inhibitor that is being tested as an addition to
standard of care treatment that includes radiotherapy and TMZ. MBM-02's ability to increase
progression free survival and decrease side effects of TMZ and radiotherapy treatment will be
assessed.